R. Fonseca, P. Bergsagel, J. Drach, J. Shaughnessy, N. Gutierrez et al., International Myeloma Working Group molecular classification of multiple myeloma: spotlight review, Leukemia, vol.91, issue.12, pp.2210-2231, 2009.
DOI : 10.1016/j.beha.2007.08.004

G. Mateo, M. Montalban, M. Vidriales, J. Lahuerta, M. Mateos et al., Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy, Journal of Clinical Oncology, vol.26, issue.16, pp.2737-2781, 2008.
DOI : 10.1200/JCO.2007.15.4120

R. Garand, H. Avet-loiseau, F. Accard, P. Moreau, J. Harousseau et al., t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma, Leukemia, vol.17, issue.10, pp.2032-2037, 2003.
DOI : 10.1038/sj.leu.2403091

T. Hideshima, P. Bergsagel, W. Kuehl, and K. Anderson, Advances in biology of multiple myeloma: clinical applications, Blood, vol.104, issue.3, pp.607-625, 2004.
DOI : 10.1182/blood-2004-01-0037

F. Zhan, Y. Huang, S. Colla, J. Stewart, I. Hanamura et al., The molecular classification of multiple myeloma, Blood, vol.108, issue.6, pp.2020-2028, 2006.
DOI : 10.1182/blood-2005-11-013458

J. Shaughnessy, J. Zhan, F. Burington, B. Huang, Y. Colla et al., A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1 Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling Characterization of MYC translocations in multiple myeloma cell lines, Blood. J Clin Oncol. Cancer Res. J Natl Cancer Inst Monogr, vol.1092667, issue.1239, pp.2276-844798, 2007.

M. Kawano, T. Hirano, T. Matsuda, T. Taga, Y. Horii et al., Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas, Nature, vol.332, issue.6159, pp.83-88, 1988.
DOI : 10.1038/332083a0

X. Zhang, R. Bataille, J. Widjenes, and B. Klein, Interleukin-6 dependence of advanced malignant plasma cell dyscrasias, Cancer, vol.78, issue.6, pp.1373-1379, 1992.
DOI : 10.1002/1097-0142(19920315)69:6<1373::AID-CNCR2820690612>3.0.CO;2-1

R. Bataille, G. Jego, N. Robillard, S. Barille-nion, J. Harousseau et al., The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy, Haematologica, vol.91, issue.9, pp.1234-1274, 2006.

J. Moreaux, D. Hose, J. M. Reme, T. Hundemer, M. Moos et al., TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines, Haematologica, vol.92, issue.6, pp.803-814, 2007.
DOI : 10.3324/haematol.10574
URL : https://hal.archives-ouvertes.fr/inserm-00162002

A. Sprynski, D. Hose, L. Caillot, T. Reme, J. Shaughnessy et al., The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor, Blood, vol.113, issue.19, pp.4614-4640, 2009.
DOI : 10.1182/blood-2008-07-170464
URL : https://hal.archives-ouvertes.fr/inserm-00367812

M. Collette, G. Descamps, C. Pellat-deceunynck, R. Bataille, and M. Amiot, Crucial role of phosphatase CD45 in determining signaling and proliferation of human myeloma cells, Eur Cytokine Netw, vol.18, issue.3, pp.120-126, 2007.

F. Zhan, J. Hardin, B. Kordsmeier, K. Bumm, M. Zheng et al., Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses, Blood. Genes Chromosomes Cancer, vol.9942, issue.222, pp.1745-57117, 2002.

C. Rebouissou, J. Wijdenes, P. Autissier, K. Tarte, V. Costes et al., A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma, Blood, vol.91, issue.12, pp.4727-4764, 1998.

K. Tarte, X. Zhang, E. Legouffe, C. Hertog, M. Mehtali et al., Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells, J Immunol, vol.163, issue.1, pp.514-538, 1999.

Z. Gu, J. Vos, C. Rebouissou, J. M. Zhang, X. Rossi et al., Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors, Leukemia, vol.14, issue.1, pp.188-97, 2000.
DOI : 10.1038/sj.leu.2401632

S. Popp, A. Jauch, D. Schindler, M. Speicher, C. Lengauer et al., A strategy for the characterization of minute chromosome rearrangements using multiple color fluorescence in situ hybridization with chromosome-specific DNA libraries and YAC clones Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients, Hum Genet. Ann Hematol, vol.9282, issue.2710, pp.527-32654, 1993.

T. Reme, T. Meissner, J. Moreaux, A. Seckinger, and J. Lewis, Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma, Blood. Blood, vol.107113, issue.718, pp.4331-4371, 2006.

J. Moreaux, F. Cremer, T. Reme, M. Raab, K. Mahtouk et al., The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature, Blood, vol.106, issue.3, pp.1021-1051, 2005.
DOI : 10.1182/blood-2004-11-4512
URL : https://hal.archives-ouvertes.fr/inserm-00129406

D. Vos, J. Thykjaer, T. Tarte, K. Ensslen, M. Raynaud et al., Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript, Oncogene. Blood, vol.21101, issue.326, pp.6848-572374, 2002.

T. Reme, D. Hose, D. Vos, J. Vassal, A. Poulain et al., A new method for class prediction based on signed-rank algorithms applied to Affymetrix?? microarray experiments, BMC Bioinformatics, vol.9, issue.1, pp.16-34, 2008.
DOI : 10.1186/1471-2105-9-16
URL : https://hal.archives-ouvertes.fr/inserm-00268075

S. Assou, L. Carrour, T. Tondeur, S. Strom, S. Gabelle et al., A Meta-Analysis of Human Embryonic Stem Cells Transcriptome Integrated into a Web-Based Expression Atlas, Stem Cells, vol.22, issue.4, pp.961-73, 2007.
DOI : 10.1634/stemcells.2006-0352
URL : https://hal.archives-ouvertes.fr/inserm-00128925

X. Cui, G. Churchill, G. Descamps, P. Gomez-bougie, C. Venot et al., Statistical tests for differential expression in cDNA microarray experiments A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomibinduced apoptosis in myeloma cells lacking CD45, Genome Biol. Br J Cancer, vol.4100, issue.42, pp.210-36366, 2003.

M. Mahmoud, H. Ishikawa, R. Fujii, M. Kawano, H. Yasukawa et al., Induction of CD45 expression and proliferation in U-266 myeloma cell line by interleukin-6, Blood, vol.92, issue.38, pp.3887-97, 1998.

N. Tsuyama, I. Danjoh, K. Otsuyama, M. Obata, H. Tahara et al., IL-6- induced Bcl6 variant 2 supports IL-6-dependent myeloma cell proliferation and survival through STAT3 Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma Classical and/or alternative NF{kappa}B pathway activation in multiple myeloma, Nat Immunol. Biochem Biophys Res Commun. Cancer Cell. Blood, vol.433712115, issue.40217, pp.551-6201, 2003.

Y. Zhou, B. Barlogie, J. Shaughnessy, and J. , The molecular characterization and clinical management of multiple myeloma in the post-genome era, Leukemia, vol.12, issue.11, pp.1941-56, 2009.
DOI : 10.1158/1078-0432.CCR-07-4568

S. Liu, K. Otsuyama, Z. Ma, S. Abroun, K. Shamsasenjan et al., Induction of Multilineage Markers in Human Myeloma Cells and Their Down-Regulation by Interleukin 6, International Journal of Hematology, vol.85, issue.1, pp.49-58, 2007.
DOI : 10.1532/IJH97.06132

'. H. I&j-$-ib%-'#%, . G. Bk&-/-f-'l-"-fg-'8727m995-'j, and %. %f-)-''n-'9g&-'h&b-/-'&+, 123456'71*74486'9*8::944'"/'FG&'@'8727#T)UVW)

A. &cd-'e-"-#e, 34'35&%+66' /$%5"5+6'+,7'&5&,2-4%&&'/$%5"5+6'34'8'9.:;'#&, <3%&'7&=,&7'63>2E&' 9.'<3E3%2'+,7'2E&'I:J:-KKL'<3E3%2)